Lancet (London, England) · 2015
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
СтатьяПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ong Albert C M, Devuyst Olivier, Knebelmann Bertrand, Walz Gerd, ERA-EDTA Working Group for Inherited Kidney Diseases
Аннотация
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease and accounts for 7-10% of all patients on renal replacement therapy worldwide. Although first reported 500 years ago, this disorder is still regarded as untreatable and its pathogenesis is poorly understood despite much study. During the past 40 years, however, remarkable advances have transformed our understanding of how the disease develops and have led to rapid changes in diagnosis, prognosis, and treatment, especially during the past decade. This Review will summarise the key findings, highlight recent developments, and look ahead to the changes in clinical practice that will likely arise from the adoption of a new management framework for this major kidney disease.
Предметные рубрики MeSH
AdolescentAdultAgedChildCyclic AMPFemaleForecastingGenetic TestingHumansMaleMiddle AgedMutationPolycystic Kidney, Autosomal DominantPrognosisProtein Serine-Threonine KinasesPyruvate Dehydrogenase Acetyl-Transferring KinaseSignal TransductionTOR Serine-Threonine KinasesTRPP Cation ChannelsYoung Adult